[Trial Data] ATTAIN-1 numbers, and why the % is not the headline
ATTAIN-1 numbers, and why the % is not the headline. I have gone back and forth on this for months.
Read both programme names carefully after mixing them up in a comment and being politely corrected.
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
Assumed the peptide purity conversations transferred and they do not. Different analytical problem entirely.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Corrected a cross-class dose comparison in the title. The body is untouched.
Daily dosing, so what does the exposure profile look like across the day?
Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.
What did the tolerability table look like at that dose?
The analytical point, which this board keeps getting wrong by importing habits from the peptide side.
For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.
So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.
[deleted]
Which programme and which readout are you quoting?
oral and non-peptide is the whole engineering story
identity testing on a small molecule is a different analytical problem
Are you comparing doses across a small molecule and a peptide?
Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.
Same view. The analytical problem is different enough that the usual purity discussions here do not transfer cleanly.
Cosigning on daily dosing. It changes the exposure profile and it changes adherence, in both directions.
the manufacturing story is genuinely different from the injectables